Trials: Genitourinary Cancer

Disease sites included: Adrenal, Bladder, Kidney, Penile, Prostate, Testicular

You are here:

Find a Clinical Trial
Genitourinary Cancer

NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

August 12, 2025

NCT02305654 – EA8134 InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

October 30, 2025

NCT03609216 – A031701 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

October 30, 2025

NCT03678025 – S1802 “Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

August 12, 2025

NCT04134260 – NRG-GU008 Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE) INtensifying treatment for NOde positive prostate cancer by Varying the hormonal Therapy

August 12, 2025

NCT05050084 – NRG GU010 “Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)”

August 12, 2025

NCT05327686 – NRG-GU012 – Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

August 12, 2025

NCT05946213 – NRG-GU013, “The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer”

October 30, 2025

NCT06044025 – A feasibility Study Evaluating a Role for Maintenance therapy in Patients with Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

December 4, 2025

NCT06470243 – S2312, “A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature”

August 12, 2025

NCT06567743 – A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

February 3, 2026